New Drug Therapies for Small Cell Carcinoma of the Lung

Lawrence H. Einhorn, John McClean, Kenneth Pennington, Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study. Seminars in Oncology. ,vol. 17, pp. 32- 35 ,(1990) , 10.5555/URI:PII:009377549090069F

P J Loehrer, R Ansari, R Gonin, F Monaco, W Fisher, A Sandler, L H Einhorn, Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. Journal of Clinical Oncology. ,vol. 13, pp. 2594- 2599 ,(1995) , 10.1200/JCO.1995.13.10.2594

Roman Perez-Soler, Bonnie S Glisson, Jin S Lee, Frank V Fossella, William K Murphy, Dong M Shin, Waun K Hong, None, Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. Journal of Clinical Oncology. ,vol. 14, pp. 2785- 2790 ,(1996) , 10.1200/JCO.1996.14.10.2785

E A Faylona, P J Loehrer, R Ansari, A B Sandler, R Gonin, L H Einhorn, Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial. Journal of Clinical Oncology. ,vol. 13, pp. 1209- 1214 ,(1995) , 10.1200/JCO.1995.13.5.1209

R Feld, W K Evans, P Coy, I Hodson, A S MacDonald, D Osoba, D Payne, W Shelley, J L Pater, Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. Journal of Clinical Oncology. ,vol. 5, pp. 1401- 1409 ,(1987) , 10.1200/JCO.1987.5.9.1401

Dimosthenis V Skarlos, E Samantas, P Kosmidis, George Fountzilas, M Angelidou, Ph Palamidas, N Mylonakis, A Provata, E Papadakis, G Klouvas, D Theocharis, E Panousaki, E Boleti, G Sphakianoudis, Nicholas Pavlidis, Lung Cancer Study Group, Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer A Hellenic Co-operative Oncology Group study Annals of Oncology. ,vol. 5, pp. 601- 607 ,(1994) , 10.1093/OXFORDJOURNALS.ANNONC.A058931

A A Miller, J E Herndon, D R Hollis, J Ellerton, A Langleben, F Richards, M R Green, Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. Journal of Clinical Oncology. ,vol. 13, pp. 1871- 1879 ,(1995) , 10.1200/JCO.1995.13.8.1871

N Masuda, M Fukuoka, Y Kusunoki, K Matsui, N Takifuji, S Kudoh, S Negoro, M Nishioka, K Nakagawa, M Takada, CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. Journal of Clinical Oncology. ,vol. 10, pp. 1225- 1229 ,(1992) , 10.1200/JCO.1992.10.8.1225

E K Rowinsky, L B Grochow, C B Hendricks, D S Ettinger, A A Forastiere, L A Hurowitz, W P McGuire, S E Sartorius, B G Lubejko, S H Kaufmann, Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. Journal of Clinical Oncology. ,vol. 10, pp. 647- 656 ,(1992) , 10.1200/JCO.1992.10.4.647

M L Slevin, P I Clark, S P Joel, S Malik, R J Osborne, W M Gregory, D G Lowe, R H Reznek, P F Wrigley, A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. Journal of Clinical Oncology. ,vol. 7, pp. 1333- 1340 ,(1989) , 10.1200/JCO.1989.7.9.1333